ResultsIQ

ResultsIQ › Latest results › Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. Q2 FY27 earnings call summary

NSE: LALPATHLAB · BSE: 539524

Earnings call of 4 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹874 cr, up 19.6%, with FY27 guidance of high-teens revenue growth and EBITDA margin slightly better than last year's 27.2%.

Key takeaways

  1. Volume driver Patient volume up 9% to 9 million and sample volume up 13.6% to 28.8 million, broad-based across regions.
  2. Margin risk Gross margin may not keep improving because of inflationary costs from the dollar, geopolitics and wage and PF changes.

Original filing on BSE

Dr. Lal Path Labs Ltd. Q2 FY27 results

As filed: Revenue ₹874 cr (+20% year on year), EBITDA ₹280 cr (+25% year on year), PAT ₹194 cr (+28% year on year), EBITDA margin 32.1% (+128 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹798 cr (+19% year on year), EBITDA ₹248 cr (+28% year on year), PAT ₹171 cr (+27% year on year), EBITDA margin 31.0% (+222 bps). Score 84 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was in line with it. EBITDA margin rose 222 bps year on year. Revenue rose ₹128 cr on a year ago, more than the ₹68.0 cr it added the year before. Share price after the results: +12.3% in 28 days (Nifty 500: +2.4%).
  • Q4 FY26: Revenue ₹703 cr (+17% year on year), EBITDA ₹187 cr (+11% year on year), PAT ₹132 cr (−15% year on year), EBITDA margin 26.6% (−128 bps). Score 44 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 128 bps year on year. Revenue rose ₹99.7 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: +15.0% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹660 cr (+11% year on year), EBITDA ₹179 cr (+16% year on year), PAT ₹91.4 cr (+12% year on year), EBITDA margin 27.2% (+138 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit before exceptional items growth was well below it. EBITDA margin rose 138 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue fell 10% from last quarter. Revenue rose ₹62.8 cr on a year ago, more than the ₹58.0 cr it added the year before. Share price after the results: −1.1% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹731 cr (+11% year on year), EBITDA ₹225 cr (+11% year on year), PAT ₹152 cr (+16% year on year), EBITDA margin 30.8% (+17 bps). Score 47 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 17 bps year on year. Profit rose ₹21.0 cr on a year ago, more than the ₹20.0 cr it added the year before. Share price after the results: −1.2% in 28 days (Nifty 500: +0.4%).
  • Q1 FY26: Revenue ₹670 cr (+11% year on year), EBITDA ₹193 cr (+14% year on year), PAT ₹134 cr (+24% year on year), EBITDA margin 28.8% (+57 bps). Score 51 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 57 bps year on year. Profit fell 14% from last quarter. Revenue rose ₹68.0 cr on a year ago, more than the ₹61.0 cr it added the year before. Share price after the results: +6.8% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹603 cr (+11% year on year), EBITDA ₹168 cr (+15% year on year), PAT ₹156 cr (+81% year on year), EBITDA margin 27.9% (+107 bps). Score 55 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well above it. EBITDA margin rose 107 bps year on year. Tax rate -1%. Revenue rose ₹58.0 cr on a year ago, more than the ₹54.0 cr it added the year before. Share price after the results: +2.2% in 28 days (Nifty 500: +2.7%).
  • Q3 FY25: Revenue ₹597 cr (+11% year on year), EBITDA ₹154 cr (+9% year on year), PAT ₹98.0 cr (+20% year on year), EBITDA margin 25.8% (−36 bps). Score 36 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 36 bps year on year. Revenue fell 10% from last quarter. Revenue rose ₹58.0 cr on a year ago, more than the ₹50.0 cr it added the year before.

Past price moves after results do not indicate future moves. Not a recommendation.

Dr. Lal Path Labs Ltd. earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.